Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's CEO, Brian Lian, Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, from 1:30 to 2:10 p.m. Pacific time at The Westin St. Francis San Francisco on Union Square.
The presentation will be accessible via live webcast through the Viking Therapeutics website's Investors & Media section under Webcasts. A replay will be available on the company's website after the conference. Dr. Lian will also participate in one-on-one meetings during the event.
Viking Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for metabolic and endocrine disorders.
Viking Therapeutics (NASDAQ: VKTX) ha annunciato la sua partecipazione alla 43陋 Conferenza Annuale sulla Salute J.P. Morgan, prevista per il 13-16 gennaio 2025 a San Francisco. Il CEO dell'azienda, Brian Lian, Ph.D., presenter脿 un intervento aziendale luned矛 13 gennaio 2025, dalle 13:30 alle 14:10 ora pacifica, presso il The Westin St. Francis di San Francisco, in Union Square.
La presentazione sar脿 accessibile tramite webcast dal vivo nella sezione Investitori & Media del sito web di Viking Therapeutics, sotto Webcast. Una registrazione sar脿 disponibile sul sito dell'azienda dopo la conferenza. Il Dr. Lian parteciper脿 inoltre a incontri individuali durante l'evento.
Viking Therapeutics 猫 una azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie innovative per i disturbi metabolici ed endocrini.
Viking Therapeutics (NASDAQ: VKTX) ha anunciado su participaci贸n en la 43陋 Conferencia Anual de Atenci贸n M茅dica J.P. Morgan, programada para el 13-16 de enero de 2025 en San Francisco. El CEO de la compa帽铆a, Brian Lian, Ph.D., realizar谩 una presentaci贸n corporativa el lunes 13 de enero de 2025, de 1:30 a 2:10 p.m., hora del Pac铆fico, en el The Westin St. Francis de San Francisco en Union Square.
La presentaci贸n estar谩 disponible a trav茅s de una retransmisi贸n en vivo en la secci贸n de Inversores y Medios del sitio web de Viking Therapeutics, bajo Webcasts. Se ofrecer谩 una repetici贸n en el sitio web de la compa帽铆a despu茅s de la conferencia. El Dr. Lian tambi茅n participar谩 en reuniones individuales durante el evento.
Viking Therapeutics es una compa帽铆a biofarmac茅utica en etapa cl铆nica que se especializa en el desarrollo de terapias novedosas para trastornos metab贸licos y endocrinos.
Viking Therapeutics (NASDAQ: VKTX)電� 2025雲� 1鞗� 13鞚茧秬韯� 16鞚缄箤歆� 靸岉攧霝�鞁滌姢旖旍棎靹� 鞐措Μ電� 鞝�43須� JP氇贝 項姢旒�鞏� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� CEO鞚� Brian Lian 氚曥偓臧� 2025雲� 1鞗� 13鞚� 鞗旍殧鞚� 韮滍弶鞏� 響滌鞁滌棎 霐半澕 鞓ろ泟 1:30攵�韯� 2:10旯岇 靸岉攧霝�鞁滌姢旖� 鞙犽媹鞓� 鞀ろ�橃柎鞚� Westin St. Francis 順疙厰鞐愳劀 旮办梾 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
氚滍憸電� Viking Therapeutics 鞗轨偓鞚错姼鞚� 韴瀽鞛� 氚� 氙鸽敂鞏� 靹轨厴 鞎勲灅 'Webcasts'毳� 韱淀暣 鞁れ嫓臧� 鞗轨簮鞀ろ姼搿� 鞝滉车霅╇媹雼�. 旎嵓霟办姢 鞚错泟 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞛儩鞚� 臧�電ロ暕雼堧嫟. Lian 氚曥偓電� 霕愴暅 頄夓偓 欷� 鞚茧寑鞚� 須岇潣鞐� 彀胳棳頃� 瓴冹瀰雼堧嫟.
Viking Therapeutics電� 雽�靷� 氚� 雮措秳牍� 鞛レ暊毳� 鞙勴暅 順侅嫚鞝侅澑 旃橂氩� 臧滊皽鞐� 鞝勲頇旊悳 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓鞛呺媹雼�.
Viking Therapeutics (NASDAQ: VKTX) a annonc茅 sa participation 脿 la 43猫me Conf茅rence Annuelle sur la Sant茅 J.P. Morgan, pr茅vue du 13 au 16 janvier 2025 脿 San Francisco. Le PDG de la soci茅t茅, Brian Lian, Ph.D., fera une pr茅sentation d'entreprise le lundi 13 janvier 2025, de 13h30 脿 14h10, heure du Pacifique, au The Westin St. Francis de San Francisco sur Union Square.
La pr茅sentation sera accessible par webdiffusion en direct via la section Investisseurs & M茅dias du site Web de Viking Therapeutics, sous Webcasts. Un enregistrement sera disponible sur le site de l'entreprise apr猫s la conf茅rence. Dr. Lian participera 茅galement 脿 des r茅unions individuelles pendant l'茅v茅nement.
Viking Therapeutics est une entreprise biopharmaceutique en phase clinique qui se sp茅cialise dans le d茅veloppement de th茅rapies novatrices pour les troubles m茅taboliques et endocriniens.
Viking Therapeutics (NASDAQ: VKTX) hat seine Teilnahme an der 43. j盲hrlichen J.P. Morgan Gesundheitskonferenz angek眉ndigt, die vom 13. bis 16. Januar 2025 in San Francisco stattfinden wird. Der CEO des Unternehmens, Brian Lian, Ph.D., wird am Montag, den 13. Januar 2025, von 13:30 bis 14:10 Uhr pazifischer Zeit eine Unternehmenspr盲sentation im The Westin St. Francis San Francisco in der Union Square halten.
Die Pr盲sentation wird 眉ber einen Live-Webcast 眉ber den Investoren- und Medienbereich der Website von Viking Therapeutics unter Webcasts zug盲nglich sein. Eine Aufzeichnung wird nach der Konferenz auf der Website des Unternehmens verf眉gbar sein. Dr. Lian wird auch an Einzelgespr盲chen w盲hrend der Veranstaltung teilnehmen.
Viking Therapeutics ist ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung neuer Therapien f眉r Stoffwechsel- und endokrine St枚rungen spezialisiert hat.
- None.
- None.
Details are as follows:
- 43rd Annual J.P. Morgan Healthcare Conference
Details: Dr. Lian will deliver a corporate presentation and participate in 1-on-1 meetings
Conference dates: January 13-16, 2025
Presentation Timing: 1:30 鈥� 2:10 p.m. Pacific on Monday, January 13, 2025
Location: The Westin St. Francis San Francisco on Union Square; webcast available
A live webcast of the presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under聽.聽 Additionally, a replay of the webcast will be available on the Viking website following the conference.聽
About Viking Therapeutics, Inc.聽
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. 聽The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.聽 In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).聽 In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit聽www.vikingtherapeutics.com.
View original content to download multimedia:
SOURCE Viking Therapeutics, Inc.
FAQ
When is Viking Therapeutics (VKTX) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Viking Therapeutics' (VKTX) J.P. Morgan Conference presentation?
What is the focus of Viking Therapeutics' (VKTX) research and development?
Where will the Viking Therapeutics (VKTX) J.P. Morgan Healthcare Conference presentation take place?
Will Viking Therapeutics (VKTX) be conducting individual meetings at the J.P. Morgan Healthcare Conference?
